{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:18:57Z","timestamp":1793215137944,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1136\/ard-2022-222405","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T17:25:43Z","timestamp":1659547543000},"page":"1491-1503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"title":["Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial"],"prefix":"10.1016","volume":"81","clinical-trial-number":[{"clinical-trial-number":"nct02092467","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0688-9173","authenticated-orcid":false,"given":"Andra-Rodica","family":"Balanescu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-1874","authenticated-orcid":false,"given":"Gustavo","family":"Citera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7368-498X","authenticated-orcid":false,"given":"Virginia","family":"Pascual-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A","family":"Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"All-Shine","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gosford","family":"Sawyerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea B","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-5302","authenticated-orcid":false,"given":"Janet E","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-491X","authenticated-orcid":false,"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-222405_bib1","first-page":"347","article-title":"One year in review 2019: pathogenesis of rheumatoid arthritis","volume":"37","author":"Croia","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-222405_bib2","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222405_bib3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/rheumatology\/kes305","article-title":"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment","volume":"52","author":"Listing","year":"2013","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222405_bib4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/rheumatology\/kel332","article-title":"What kills patients with rheumatoid arthritis?","volume":"46","author":"Kelly","year":"2007","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-222405_bib5","first-page":"S35","article-title":"Mortality in rheumatoid arthritis: 2008 update","volume":"26","author":"Sokka","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-222405_bib6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","article-title":"Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis","volume":"61","author":"Du Pan","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222405_bib7","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-222405_bib8","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/art.41754","article-title":"Nonserious infections in patients with rheumatoid arthritis: results from the British Society for rheumatology biologics register for rheumatoid arthritis","volume":"73","author":"Bechman","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222405_bib9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/annrheumdis-2012-201338","article-title":"Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch rheumatoid arthritis monitoring (DREAM) registry","volume":"72","author":"van Dartel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222405_bib10","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-Specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222405_bib11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","article-title":"Long-Term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry","volume":"12","author":"Atzeni","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1136\/ard-2022-222405_bib12","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/S2665-9913(19)30137-7","article-title":"Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study","volume":"2","author":"Pawar","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2022-222405_bib13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-222405_bib14","author":"European Medicines Agency"},{"key":"10.1136\/ard-2022-222405_bib15","author":"European Medicines Agency"},{"key":"10.1136\/ard-2022-222405_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-Term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-222405_bib17","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0010-4825(92)90023-G","article-title":"Simple SAS macros for the calculation of exact binomial and Poisson confidence limits","volume":"22","author":"Daly","year":"1992","journal-title":"Comput Biol Med"},{"key":"10.1136\/ard-2022-222405_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"10.1136\/ard-2022-222405_bib19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13075-017-1466-y","article-title":"Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment","volume":"19","author":"Curtis","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-222405_bib20","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2022-222405_bib21","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/fampra\/cmaa105","article-title":"Burden of infections on older patients presenting to general practice: a registry-based study","volume":"38","author":"Struyf","year":"2021","journal-title":"Fam Pract"},{"key":"10.1136\/ard-2022-222405_bib22","first-page":"390","article-title":"Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis","volume":"35","author":"Curtis","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-222405_bib23","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/annrheumdis-2020-218992","article-title":"Age-based (<65 vs \u226565 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry","volume":"80","author":"Winthrop","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222405_bib24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/acr2.11232","article-title":"Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry","volume":"3","author":"Kremer","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2022-222405_bib25","author":"Pfizer Inc"},{"key":"10.1136\/ard-2022-222405_bib26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/BOR.0000000000000598","article-title":"Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?","volume":"31","author":"Jani","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard-2022-222405_bib27","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/art.39462","article-title":"Opioid analgesics and the risk of serious infections among patients with rheumatoid arthritis: a self-controlled case series study","volume":"68","author":"Wiese","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-222405_bib28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/annrheumdis-2021-220651","article-title":"Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register","volume":"81","author":"Redeker","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-222405_bib29","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.semarthrit.2018.07.006","article-title":"A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a phase 3 rheumatoid arthritis population","volume":"48","author":"Kivitz","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard-2022-222405_bib30","article-title":"Variable selection strategies and its importance in clinical prediction modelling","volume":"8","author":"Chowdhury","year":"2020","journal-title":"Fam Med Community Health"},{"key":"10.1136\/ard-2022-222405_bib31","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/bimj.201700067","article-title":"Variable selection - A review and recommendations for the practicing statistician","volume":"60","author":"Heinze","year":"2018","journal-title":"Biom J"},{"issue":"Suppl 10","key":"10.1136\/ard-2022-222405_bib32","article-title":"The risk of venous thromboembolic events in patients with RA aged \u226550 years with \u22651 cardiovascular risk factor: results from a phase 3b\/4 randomized safety study of tofacitinib vs TNF inhibitors [abstract]","volume":"73","author":"Charles-Schoeman","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 10","key":"10.1136\/ard-2022-222405_bib33","article-title":"Incidence of infections in patients aged \u2265 50 years with RA and \u2265 1 additional cardiovascular risk factor: results from a Phase 3b\/4 randomized safety study of tofacitinib vs TNF inhibitors [abstract]","volume":"73","author":"B\u0103l\u0103nescu","year":"2021","journal-title":"Arthritis Rheumatol"}],"updated-by":[{"DOI":"10.1136\/ard-2022-222405corr1","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000}}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724183896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724183896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-222405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:41:52Z","timestamp":1739522512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724183896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0003496724183896"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-222405","relation":{"erratum":[{"id-type":"doi","id":"10.1136\/ard-2022-222405corr1","asserted-by":"object"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-222405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 \u00a9 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}